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Abstract Radiographic endpoints including response and
progression are important for the evaluation of new glioblas-
toma therapies. The current RANO criteria was developed to
overcome many of the challenges identified with previous
guidelines for response assessment, however, significant chal-
lenges and limitations remain. The current recommendations
build on the strengths of the current RANO criteria, while
addressing many of these limitations. Modifications to the
current RANO criteria include suggestions for volumetric re-
sponse evaluation, use contrast enhanced T1 subtraction maps
to increase lesion conspicuity, removal of qualitative non-
enhancing tumor assessment requirements, use of the post-
radiation time point as the baseline for newly diagnosed glio-
blastoma response assessment, and Btreatment-agnostic^ re-
sponse assessment rubrics for identifying pseudoprogression,
pseudoresponse, and a confirmed durable response in newly
diagnosed and recurrent glioblastoma trials.
Keywords Glioblastoma .GBM .ResponseAssessment . T1
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Introduction
Approximately 89,000 new primary brain tumors are diag-
nosed in the United States each year, for which 27% are glio-
mas and 32.8% are malignant [1]. Glioblastoma (GBM) oc-
curs in approximately 46% of gliomas [1] and has a poor
prognosis of around 14 months median survival [2] and less
than 10% of patients live longer than 5 years from diagnosis
[3]. The current standard of care for newly diagnosed GBM
patients consists of maximum safe surgical resection followed
by external beam radiation therapy plus concomitant and ad-
juvant temozolomide [2], particularly in patients that demon-
strate O6-methylguanine-methyltransferase (MGMT) pro-
moter methylation. At recurrence there is no consensus as to
the standard of care as no therapeutic options have produced
substantial survival benefit [4].
Although overall survival (OS) is the standard for deter-
mining GBM treatment efficacy, using OS as an endpoint
when studying new therapeutic strategies can be problematic
because of potential influence of therapies prior to or subse-
quently following the therapy being studied. For example, it is
difficult to definitively conclude that bevacizumab has no ef-
ficacy in GBM when a large percentage of patients in the
placebo arms in both III trials studying efficacy of
bevacizumab (i.e. AVAglio and RTOG-0825) eventually
crossed over and received bevacizumab (31% in AVAglio
[5] and 48% in RTOG-0825 [6]). If bevacizumab increased
OS when given at any time during treatment, we may expect
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both treatment arms to have similar median OS since most
patients eventually were treated with bevacizumab, disguising
any therapeutic effects of the drug. Together, these results
suggest OS may not be a suitable endpoint when studying
new therapeutics or when there is a high chance of cross over
in the control arm.
To overcome the limitations associated with using OS as
the primary endpoint in studies involving new therapeutics,
progression-free survival (PFS) and objective response rate
(ORR) should be considered important end points [7].
However, PFS and ORR also have challenges, as determina-
tion of response and progression using anatomic imaging
techniques may suffer from issues associated with measure-
ment variability and discordance in interpretation between ra-
diologists [8]. Therefore, it is important to develop both new
response guidelines for identifying these issues as well as new
imaging tools for better differentiating treatment-related
changes from changes associated with non-responsive, grow-
ing tumor.
The goal of this modified response criteria is to mean-
ingfully evaluate radiographic response and progression
while simultaneously allowing therapies that may have
transient effects on contrast enhancement but therapeutic
benefit to be treated equally. This is particularly important
in the context of platform trials, where many different
therapies may be compared against a common control
and there is a significant risk of over or under estimating
tumor burden with a single evaluation time point. By
allowing patients to stay on therapy longer, a more com-
prehensive and accurate assessment of therapeutic benefit
can be performed on retrospective examination. A univer-
sal set of principles and guidelines, rather than treatment-
specific response criteria, may allow us to fully under-
stand the possible therapeutic benefits and potential limi-
tations of promising new therapies for patients with GBM.
Brief History of Radiologic Response Assessment
in GBM
The formation of new blood vessels, or angiogenesis, is critical
for the growth of malignant brain tumors [9–11]. Malignant
gliomas with high neovascularity or vascular permeability
[12–14] are often associated with higher proliferation rates
[15] and higher degree of aggressivity. Because of this associ-
ation, imaging techniques aimed at identifying abnormal vas-
cularity or vascular permeability, including contrast-enhanced
computed tomography (CT) and magnetic resonance imaging
(MRI) are commonly used for diagnosis and clinical manage-
ment of brain tumors, as they have been shown to contain the
most aggressive portions of the tumor [16, 17].
In 1990, Macdonald et al. [18] introduced the first radio-
graphic response assessment specific to brain tumors by
significantly improving upon the Levin criteria [19] and the
WHO oncology response criteria [20]. By standardizing the
definition of radiographic response using quantitative bidirec-
tional measurements and accounting for corticosteroid use in
neurological status, similar to the response evaluation criteria
in solid tumors (RECIST) [21], the new BMacdonald criteria^
utilized measurements of contrast enhancing tumor size com-
bined with other clinical metrics to determine treatment re-
sponse and tumor progression by stratifying response into four
categories: complete response (CR), partial response (PR),
stable disease (SD), and progressive disease (PD). The origi-
nal Macdonald criteria continues to be the fundamental frame-
work for response assessment and radiographic interpretation
of treatment changes in neuro-oncology, having been used for
more than 20 years.
Known Limitations for Current Response Criteria
Although contrast enhancement has been used to assess
brain tumor response for more than 60 years and contrast
enhancement is generally a strong surrogate of brain tumor
disease, there are caveats and exceptions that have been
discovered as a result of different treatment mechanisms
that affect vascular permeability. For example, increased
vascular permeability from cytotoxic therapies including
radiotherapy and anti-neoplastic treatments have been
shown to result in increased contrast enhancement in the
context of therapeutic benefit, a phenomena known as
Bpseudoprogression.^ Additionally, clinical studies exam-
ining the efficacy of new anti-angiogenic agents have
noticed a substantial decrease in contrast enhancement
[22–31] resulting in high response rates, ranging from 28
to 63% in bevacizumab [32–34] and 50% in cediranib [31]
compared with < 10% using other chemotherapies [35–38],
which translated into prolonged PFS but no difference in
OS [31, 32]. It was assumed this high response rate was
due to the use of contrast enhancement as the primary tool
for evaluation in the Macdonald criteria, which resulted in
a Bpseudoresponse^[39], where contrast enhancement is
falsely reduced due to changes in vascular permeability
independent of anti-tumor effect.
In addition to increased response rates, studies examining
tumor relapse/progression while on anti-angiogenic agents
note a tendency for growth of nonenhancing, infiltrative tumor
prior to emergence of contrast enhancement [25].
Approximately 30-40% of patients are estimated to experi-
ence non-enhancing tumor progression prior to changes in
contrast enhancement [40, 41]. Malignant gliomas are known
to contain proportions of both neovascularized and infiltrative
tumor [42, 43] and the relative proportions are thought to
reflect different biological phenotypes [44–48]. In 2010, ex-
pert opinion and examination of these limitations resulted in
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the creation of a formal Response Assessment in Neuro-
Oncology (RANO) criteria [49] to comprehensively reform
the Macdonald criteria using previously documented perspec-
tives and approaches [50–52].
Although the RANO criteria corrects for a number of
insufficiencies identified in the Macdonald criteria includ-
ing inclusion of the evaluation of nonenhancing tumor pro-
gression and issues associated with pseudoresponse and
pseudoprogression, there remain significant limitations to
the current standard RANO criteria given recent data. For
example, the current RANO criteria requires use of bidi-
rectional measurements of contrast enhancing tumor size,
which have been shown to overestimate tumor volume [53]
and result in higher reader discordance [8, 54–59], presum-
ably due to differences in head tilt and accurate identifica-
tion of longest and perpendicular diameter in relatively
irregular tumors. Other studies have shown reasonable
agreement between bidimensional and volumetric mea-
surements [60, 61], suggesting quick bidimensional assess-
ment of contrast enhancing tumor size may be a practical
alternative to more sophisticated volumetric segmentation.
Additionally, the thresholds used to define response and
progression is relatively arbitrary and not optimized based
on scientific data showing the best correlation with surviv-
al benefit or time to treatment failure. (Note: The efficacy
of these thresholds remains to be sufficiently challenged).
Also, the use of thresholds based on Bpercentage change^
with respect to baseline tumor size are significantly biased
toward small tumors where relatively low absolute changes
in tumor size are interpreted as a large percentage change
[61]. This is particularly an issue in newly diagnosed GBM
studies, where patients with tiny tumors often progress ear-
ly due to triggering of progression (PD) when Bnon-mea-
surable disease^, defined as having the two largest perpen-
dicular diameters of a contrast enhancing target lesion less
than 10mm, reaches the subtle threshold of Bmeasurable
disease^. Lastly, although changes in non-enhancing
disease were added to the RANO criteria in an attempt to
identify non-enhancing tumor progression, particularly in
the presence of anti-angiogenic therapy, retrospective eval-
uations in clinical trials have shown it results in PD
approximately a month prior to contrast enhancing disease
progression [62], does not result in significant differences
in prediction of OS [62, 63], and is one of the most
controversial aspects of RANO evaluation due to the
subjective nature of the interpretation and high adjudica-
tion rates. Further, studies have shown that specific aspects
of non-enhancing tumor progression (e.g. circumscribed
vs. infiltrative T2 changes) result in dramatically different
post-progression survival in GBM patients [41], suggest-
ing evaluation of non-enhancing tumor progression using
T2 and/or FLAIR may be more complex than once thought
and warrant further investigation before it can be properly
integrated as an early radiographic endpoint. Further, new
immunotherapy agents can also cause inflammation lead-
ing to changes in T2 signal intensity that is ambiguous with
regard to interpretation of changes in tumor biology.
Updated Strategies for Response Assessment
in Neuro-Oncology: Modified RANO Criteria
Based on these various challenges, an update to the current
response criteria is necessary in an attempt to establish a gen-
eral framework for response assessment in neuro-oncology
that is agnostic to the mechanism of action of the particular
therapy (e.g. anti-angiogenic, anti-neoplastic, immunotherapy,
etc.), each of which has its own challenges associated with
interpretation of radiographic changes, and is updated based
on recent scientific evidence and current clinical convention.
In order to advance the RANO criteria and address these chal-
lenges we propose the following Bmodified^ RANO criteria
for use in evaluating therapeutic efficacy in patients with
GBM.
Image Acquisition Requirements
In response to a need for better standardization of image
acquisition in GBM clinical trials [64], a recent consensus
paper was published outlining an Binternational brain tu-
mor imaging protocol (BTIP)^ (Table 1) with recom-
mended sequences and parameters [65]. At the core of
this recommended protocol is parameter matched, pre-
and post-contrast 3D (volumetric) inversion recovery gra-
dient recalled echo (IR-GRE) images with less than 1.5-
mm isotropic resolution, which allows for both
bidimensional and volumetric measurements of enhancing
tumor. When possible, this protocol should be employed
for prospective clinical trials.
If volumetric acquisition is not employed, or if retrospec-
tive evaluations of existing trial data are performed, then slice
thickness plus interslice gap should be less than 5 mm. If the
sum of the slice thickness and gap exceeds 5 mm, then slightly
modified definitions of measurable disease should be used
(e.g. measurable disease = largest perpendicular diame-
ters > 2× slice thickness + gap).
Contrast Enhanced T1-Weighted Digital Subtraction
Maps for Increased Lesion Conspicuity
Quantification of contrast enhancing tumor size or volume
should be performed on contrast-enhanced T1-weighted digi-
tal subtraction maps (Fig. 1) in order to increase lesion con-
spicuity and better predict tumor burden in the presence of
reduced vascular permeability as occurs during anti-
angiogenic therapy [66] and/or T1 shortening from blood
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products or calcifications [67, 68]. Further, the American
College of Radiology (ACR) recommends this approach for
identification and delineation of subtly enhancing bone and
soft tissue lesions [69].
Table 1 International Standardized Brain Tumor Imaging Protocol (BTIP) minimum image acquisition requirements for 1.5T and 3T MR systems
Variable 3D T1w Preb Ax 2D FLAIRj Ax 2D DWI Contrast
Injectiona
Ax 2D T2wh,i 3D T1w Postb
Sequence IR-GREe,f TSEc SS-EPIg TSEc IR-GREe,f
Plane Sagittal/Axial Axial Axial Axial Sagittal/Axial
Mode 3D 2D 2D 2D 3D
TR [ms] 2100m >6000 >5000 >2500 2100m
TE [ms] Min 100-140 Min 80-120 Min
TI [ms] 1100n 2000-2500k 1100n
Flip angle 10°-15° 90°/≥160° 90°/180° 90°/≥160° 10°-15°
Frequency ≥172 ≥256 ≥128 ≥256 ≥172
Phase ≥172 ≥256 ≥128 ≥256 ≥172
NEX ≥1 ≥1 ≥1 ≥1 ≥1
FOV 256mm 240mm 240mm 240mm 256mm
Slice thickness ≤1.5mm ≤4mml ≤4mml ≤4mml ≤1.5mm
Gap/Spacing 0 0 0 0 0
Diffusion optionsp b = 0, 500, 1000 s/mm2
≥3 directions
Parallel imaging Up to 2x Up to 2x Up to 2x Up to 2x Up to 2x
Approximate
scan time
5-10 min 4-8 min 2-4 min 4-8 min 5-10 min
Ax =Axial; ADC= apparent diffusion coefficient; FLAIR = fluid attenuated inversion recovery; DWI = diffusion-weighted imaging; 3D = three dimen-
sional; TSE = turbo spin echo; EPI = echo planar imaging; SS-EPI = single-shot echo planar imaging; GE-EPI = gradient echo echo planar imaging;
2DFL = two-dimensional FLASH (fast low angle shot) gradient recalled echo; MPRAGE=magnetization prepared rapid gradient-echo; A/P = anterior
to posterior; R/L = right to left; NEX= number of excitations or averages; FOV = field of view; TE = echo time; TR = repetition time; TI = inversion
time; PD = proton density; DSC = dynamic susceptibility contrast; IR-GRE = inversion-recovery gradient-recalled echo
a 0.1 mmol/kg dose injection with a Gadolinium chelated contrast agent. Use of a power injector is desirable at an injection rate of 3-5cc/s
b Post-contrast 3D T1-weighted images should be collected with equivalent parameters to pre-contrast 3D T1-weighted images
c TSE = turbo spin echo (Siemens & Philips) is equivalent to FSE (fast spin echo; GE, Hitachi, Toshiba)
d FL2D = two-dimensional fast low angle shot (FLASH; Siemens) is equivalent to the spoil gradient recalled echo (SPGR; GE) or T1- fast field echo
(FFE; Philips), fast field echo (FastFE; Toshiba), or the radiofrequency spoiled steady state acquisition rewound gradient echo (RSSG; Hitachi). A fast
gradient echo sequence without inversion preparation is desired
e IR-GRE = inversion-recovery gradient-recalled echo sequence is equivalent to MPRAGE=magnetization prepared rapid gradient-echo (Siemens &
Hitachi) and the inversion recovery spoiled gradient-echo (IR-SPGR or Fast SPGR with inversion activated or BRAVO; GE), 3D turbo field echo (TFE;
Philips), or 3D fast field echo (3D Fast FE; Toshiba)
f A 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE or another IR-prepped 3D T1-weighted
sequences and therefore should be avoided
g In the event of significant patient motion, a radial acquisition scheme may be used (e.g. BLADE [Siemens], PROPELLER [GE], MultiVane [Philips],
RADAR [Hitachi], or JET [Toshiba]); however, this acquisition scheme is can cause significant differences in ADC quantification and therefore should
be used only if EPI is not an option. Further, this type of acquisition takes considerably more time
hDual echo PD/T2 TSE is optional for possible quantification of tissue T2. For this sequence, the PD echo is recommended to have a TE < 25ms
i Advanced sequences can be substituted into this time slot, so long as 3D post-contrast T1-weighted images are collected between 4 and 8 min after
contrast injection
j 3D FLAIR is an optional alternative to 2D FLAIR, with sequence parameters as follows per EORTC guidelines: 3D TSE/FSE acquisition; TE = 90-
140ms; TR = 6000-10000ms; TI = 2000-2500ms (chosen based on vendor recommendations for optimized protocol and field strength); GRAPPA ≤ 2;
Fat Saturation; Slice thickness ≤ 1.5mm; Orientation Sagittal or Axial; FOV ≤ 250 mm x 250 mm; Matrix ≥ 244x244
k Choice of TI should be chosen based on the magnetic field strength of the system (e.g. TI ≈ 2000ms for 1.5T and TI ≈ 2500ms for 3T)
l In order to ensure comparable SNR older 1.5TMR systems can use contiguous (no interslice gap) images with 5mm slice thickness or increase NEX for
slice thickness ≤4mm
n For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI = 400-450ms for similar contrast
m For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR = 5-15ms for similar contrast
p Older model MR scanners that are not capable of >2 b-values should use b = 0 and 1000 s/mm2
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Bidimensional and/or Volumetric Measurements
Similar to the current RANO criteria, two-dimensional, per-
pendicular measurements of contrast enhancing tumor size,
excluding the resection cavity along with any cysts or areas
of central macroscopic necrosis, should be used for response
assessment if volumetric tools are not available. Table 2 out-
lines suggested volumetric conversions from two- to three-
dimensional measurements for consistency in response defi-
nitions, as outlined by Chappell et al. [70].
It is important to note that the field remains conflicted on
whether or not enhancing disease should be included in tumor
size measurements, or whether it is more appropriate to mon-
itor total enhancing lesion volume, which may include central
macroscopic necrosis and any cystic components (but exclud-
ing surgically resected tissue). Scientific studies have shown
that both approaches for quantifying change in tumor size as a
surrogate of treatment response are valuable. Multiple studies
utilizing the Macdonald and RANO criteria have shown that
change in enhancing disease size using bidimensional mea-
surements, excluding necrosis and cystic components, can be
used to predict survival in a variety of therapies. A recent
study from the BRAIN trial, a phase II trial of bevacizumab
with or without irinotecan in recurrent GBM, confirmed that
change in the volume of enhancing disease can be used to
predict survival benefit [66]. However, a recent study exam-
ining growth rates in treatment naïve presurgical GBMs
showed that changes in enhancing disease only may not be
reliable, since changes occurring prior to any therapy often
showed stable or decreasing tumor enhancing disease volume
[61]. Growth rates were universally positive (i.e. growing)
when total lesion volume (including central necrosis) were
taken into consideration, which appears more realistic given
the fast growth trajectory of these tumors during therapeutic
intervention. Regardless, future studies are warranted to deter-
mine which measurement may be more clinically meaningful
or reliable in predicting early response to new therapies.
Definition of Measurable Disease, Non-Measurable
Disease, and Target Lesions
Measurable disease should be defined as contrast enhancing
lesions with a minimum size of both perpendicular measure-
ments greater than or equal to 10mm (Fig. 2). For example, if
the largest diameter is 15 mm but the perpendicular diameter
is 8 mm, this would constitute non-measurable disease.
Additionally, in the event that the BTIP protocol is not used,
if the slice thickness plus interslice gap is greater than 5mm,
then the minimum size for both perpendicular measurements
should be twice the sum of the slice thickness and interslice
gap (e.g. if the slice thickness is 5mm with 1.5mm interslice
gap, the minimum tumor size on both perpendicular dimen-
sions should be 13mm). Up to a total of five target measurable
lesions should be defined and ranked from largest to smallest
(Fig. 2).
Fig. 1 Construction of contrast
enhanced T1-weighted
subtraction maps in a recurrent
glioblastoma patient treated with
bevacizumab. A) Pre-contrast T1-
weighted MR image. B) Post-
contrast T1-weighted MR image.
C) T1 subtraction map calculated
by voxel-wise subtraction of pre-
contrast from post-contrast T1-
weighted images highlighting
areas of increased contrast
enhancement. Red arrows show
two subtly enhancing lesions that
are easily identified on T1
subtraction maps
Table 2 Bidimensional to
volumetric definitions [54, 70,
96] of radiographic response and
progression
State of disease Change in bidimensional product Estimated volumetric change
Complete response (CR) 100% Decrease 100% Decrease
Partial response (PR) ≥50% Decrease ≥65% Decrease
Progressive disease (PD) ≥25% Increase ≥40% Increase
Stable disease (SD) <50% Decrease to
<25% Increase
<65% Decrease to
<40% Increase
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Non-measurable disease should be defined as lesions that
are too small to be measured (less than 1 cm in both perpen-
dicular dimensions), lesions that lack contrast enhancement
(non-enhancing disease), or lesions that contain a poorly de-
fined margin that cannot be measured or segmented with
confidence.
Correction for BBaseline Tumor Volume^ in Newly
Diagnosed and Recurrent GBM
An abundance of single center, multicenter, and phase I-III
trials have confirmed that baseline contrast enhancing tumor
size (volume or bidirectional measurements) is a significant
prognostic factor contributing to overall survival (OS) in
GBM. In newly diagnosed GBM, both extent of resection
[3, 71–87] and post-surgical residual volume [83–85, 88–92]
have been shown to be prognostic. Similarly, baseline pre-
treatment contrast enhanced tumor size has also been shown
to be prognostic for OS in recurrent GBM [53, 66, 93].
However, from a clinical trial perspective, post-surgical resid-
ual enhancing tumor volume may be a more practical mea-
surement to obtain, as pre-surgical MRI scans are often not
available or collected as part of clinical trials because patients
are not enrolled until after surgery and diagnosis. Thus, care
should be made to make sure baseline tumor size is a stratifi-
cation factor during randomization (i.e. prospectively bal-
anced across treatment arms) and used as a covariate in statis-
tical models evaluating treatment efficacy.
Post-Radiation MRI Examination as the Reference
for Evaluating Radiographic Response in Newly
Diagnosed GBM
The current RANO criterion defines the post-surgicalMRI scan
as the baseline for treatment response evaluation; however, we
propose using the post-radiation examination (i.e. the first scan
following completion of concurrent radiation therapy and che-
motherapies such as temozolomide and/or experimental thera-
peutics) as the baseline for response assessment because reli-
ability of tumor assessment on the post-surgical MR scans can
be problematic for a number of reasons. First, this scan is typ-
ically acquired prior to a final pathological diagnosis, thus pa-
tients are not yet enrolled in a clinical trial and therefore the
imaging protocol may not be consistent with trial recommen-
dations, leading to a mismatch between the baseline and sub-
sequent follow-up time points. Secondly, post-operative MR
scans are often contaminated with post-surgical changes in-
cluding blood products and increased vascular permeability
from surgical trauma. Thirdly, steroid dose can be highly var-
iable during this time and may be poorly annotated, as patients
are typically not yet enrolled in clinical trials at this point.
Additionally, the timing of the post-operative MR scans can
be highly variable from patient to patient, depending on the
complexity of the surgery and potential intraoperative compli-
cations, and institution by institution, as many factors including
availability of inpatient MR scanners can lead to different
timing of the post-surgical MRI evaluation. This variability
inevitably leads to differing degrees of post-surgical artifacts
and fluid levels on the resulting images. Together, these factors
appear to indicate the post-surgical MRI examination may not
be a reliable reference scan for accurately determining radio-
graphic changes, despite post-surgical residual enhancing vol-
ume being a significant prognostic factor as outlined above.
Perhaps the most compelling argument for using the post-
radiation scan as the baseline for determining response assess-
ment is the highly unpredictable, transient radiographic changes
that often accompany the initial chemoradiation phase (i.e. ex-
ternal beam radiation therapy plus concurrent temozolomide)
with or without experimental therapeutics.Within 1month after
completion of standard chemoradiation therapy, approximately
50% of patients will experience radiographic changes sugges-
tive of early tumor progression in reference to the post-surgical
MRI exam, of which 50% are likely to have pseudoprogression
(i.e. 25% of all patients at 1 month post-chemoradiation are
estimated to have pseudoprogression) [94]. This proportion of
patients with both early progression and pseudoprogression de-
creases steadily during the subsequent standard adjuvant che-
motherapy phase, which forms the basis for current RANO
recommendations of excluding patients in recurrent GBM trials
who progressed within 3 months after completion of chemora-
diation. Many clinicians are reluctant to change therapy based
on this examination due to the relatively high incidence of
Fig. 2 Algorithm for identifying measurable and target lesions
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treatment-related radiographic changes directly after comple-
tion of concurrent chemotherapy and radiation, and instead
use this scan as a new baseline in which to interpret subsequent
changes in tumor size. Additionally, experimental therapeutics
that significantly alter vascular permeability, including anti-
angiogenic and immunotherapies, when used concurrently with
radiation therapy and temozolomide often demonstrate dramat-
ic and transient changes in contrast enhancement that quickly
stabilize following completion of radiation [95]. Despite the
improved lesion conspicuity on T1 subtraction maps in the
settings of these therapies, these early changes between the
post-surgical, pre-radiation exam and the post-radiation exam
may not accurately reflect true changes in tumor burden nor
predict long-term survival benefit [95].
Detailed Definitions Used for Modified
Radiographic Response Assessment Criteria
Radiographic response should be determined in comparison to
the tumor measurements obtained at baseline (post-radiation
scan will be baseline for newly diagnosed GBM and pre-
treatment scans will be the baseline for recurrent GBM) for
determination of response, and the smallest tumor measure-
ment at either pre-treatment baseline or following initiation of
therapy for determining progression.
Because novel treatments are likely to result in a higher
than normal incidence of treatment-related increase in contrast
enhancement (Bpseudoprogression^, PsP) or decrease in con-
trast enhancement (Bpseudoresponse^, PsR), patients should
continue therapy with close observation (e.g. 4-8 week inter-
vals) if there is a suspicion of PsP or PsR. If subsequent im-
aging studies and/or clinical observations demonstrate that
progression in fact has occurred, the date of confirmed pro-
gression should be noted as the scan at which the potential
progression was first identified. Definitions for complete re-
sponse, partial response, progressive disease, and stable dis-
ease should be defined as follows for all target lesions.
Complete Response (CR): Requires all of the following:
1. Disappearance of all enhancing measurable and non-
measurable disease sustained for at least 4 weeks. The
first scan exhibiting disappearance of all enhancing mea-
surable and non-measurable disease is considered
Bpreliminary CR^. If the second scan exhibits measurable
enhancing disease with respect to the Bpreliminary CR^
scan, then the response is not sustained, noted as
pseudoresponse, PsR, and is now considered
Bpreliminary PD^ (note confirmed PD requires at least
two sequential increases in tumor volume). If the second
scan continues to exhibit disappearance of enhancing dis-
ease or emergence of non-measurable disease (less than
10mmbidimensional product), it is considered a durable CR
and the patient should continue on therapy until confirmed
PD is observed.
2. Patients must be off corticosteroids (or on physiologic
replacement doses only).
3. Stable or improved clinical assessments (i.e. neurological
examinations).
Note: Patients with non-measurable disease only at base-
line cannot have CR; the best response possible is stable dis-
ease (SD).
Partial Response (PR): Requires all of the following:
1. ≥50% decrease in sum of products of perpendicular diam-
eters or ≥65% decrease in total volume [54, 70, 96] of all
measurable enhancing lesions compared with baseline,
sustained for at least 4 weeks. The first scan exhibiting
≥50% decrease in sum of products of perpendicular diam-
eters or ≥65% decrease in total volume [54, 70, 96] of all
measurable enhancing lesions compared with baseline is
considered Bpreliminary PR^. If the second scan exhibits
PD with respect to the Bpreliminary PR^ scan, then the
response is not sustained, noted as pseudoresponse, PsR,
and is now considered Bpreliminary PD^ (note confirmed
PD requires at least two sequential increases in tumor
volume). If the second scan exhibits SD, PR, or CR, it is
considered a durable PR and the patient should continue
on therapy until confirmed PD is observed.
2. Steroid dose should be the same or lower compared with
baseline scan.
3. Stable or improved clinical assessments.
Note: Patients with non-measurable disease only at base-
line cannot have PR; the best response possible is stable dis-
ease (SD).
Progressive Disease (PD): Defined by any of the following:
1. At least two sequential scans separated by at ≥4 weeks
both exhibiting ≥25% increase in sum of products of per-
pendicular diameters or ≥40% increase in total volume
[54, 70, 96] of enhancing lesions. The first scan exhibiting
≥25% increase in sum of products of perpendicular diam-
eters or ≥40% increase in total volume [54, 70, 96] of
enhancing lesions should be compared to the smallest
tumor measurement obtained either at baseline (if no de-
crease) or best response (on stable or increasing steroid
dose) and is noted as Bpreliminary PD.^ If the second scan
at least 4 weeks later exhibits a subsequent ≥25% increase
in sum of products of perpendicular diameters or ≥40%
increase in total volume of enhancing lesions relative to
the Bpreliminary PD^ scan, it is considered Bconfirmed
PD^ and the patient should discontinue therapy. If the
second scan at least 4 weeks later exhibits SD or PR/
CR, this scan showing Bpreliminary PD^ is noted as
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Bpseudoprogression^, PsP, and the patient should contin-
ue on therapy until a second increase in tumor size relative
to the PsP scan is observed. Note that any new
measurable (>10mm x 10mm) enhancing lesions should
not be immediately considered PD, but instead should be
added to the sum of bidimensional products or total vol-
ume representing the entire enhancing tumor burden.
2. In the case where the baseline or best response demon-
strates no measurable enhancing disease (visible or not
visible), then any new measurable (>10mm x 10mm) en-
hancing lesions are considered PD after confirmed by a
subsequent scan ≥4 weeks exhibiting ≥25% increase in
sum of products of perpendicular diameters or ≥40% in-
crease in total volume of enhancing lesions [54, 70, 96]
relative to the scan first illustrating new measurable dis-
ease. The first scan exhibiting new measurable disease is
noted as Bpreliminary PD.^ If the second scan at least 4
weeks later exhibits a subsequent ≥25% increase in sum
of products of perpendicular diameters or ≥40% increase
in total volume [54, 70, 96] of enhancing lesions relative
to the Bpreliminary PD^ scan it is considered Bconfirmed
PD^ and the patient should discontinue therapy. If the
second scan at least 4 weeks later exhibits SD, CR, PR,
or becomes non-measurable, this scan showing
Bpreliminary PD^ is noted as Bpseudoprogression^, PsP,
and the patient should continue on therapy until a second
increase in tumor size relative to the Bpreliminary PD^, or
PsP, scan is observed. Note that any new measurable
(>10mm x 10mm) enhancing lesions on the subsequent
scan following the preliminary PD scan should not be
immediately considered confirmed PD, but instead should
be added to the sum of bidimensional products or total
volume representing the entire enhancing tumor burden.
3. Clear clinical deterioration not attributable to other causes
apart from tumor (e.g. seizures, medication adverse ef-
fects, therapy complications, stroke, infection) or attribut-
able to changes in steroid dose.
4. Failure to return for evaluation as a result of death or
deteriorating condition.
Stable Disease (SD): Requires all of the following:
1. Does not qualify for CR, PR, or PD as defined above.
Note this also applies to patients that demonstrate PsR
when the confirmation scan does not show PD or PsP
when the confirmation scan does not show PR/CR.
2. In the event that corticosteroid dose was increased (for
new symptoms/signs) without confirmation of disease
progression on neuroimaging, and subsequent follow-up
imaging shows that the steroid increase was required be-
cause of disease progression, the last scan considered to
show stable disease will be the scan obtained when the
corticosteroid dose was equivalent to the baseline dose.
Symptomatic Deterioration & Reporting Clinical Status
Patients with global deterioration of health status requiring dis-
continuation of treatment without objective evidence of disease
progression at that time, and not either related to study treat-
ment or other medical conditions, should be reported as PD due
to Bsymptomatic deterioration.^ Every effort should be made to
document the objective progression even after discontinuation
of treatment due to symptomatic deterioration. Neurological
exam data should be provided to the independent radiologic
facility as Bstable, better, worse^ in case report forms or from
study sponsor. Clinical status should be recorded as Bworse^ if
the neurological exam is worse, otherwise the clinical status
should be set to Bnot worse.^ In the event that necessary clinical
data is not available, clinical status should be recorded as Bnot
available^ and that particular time point can only be reviewed
for PD (otherwise Bnon-evaluable^). Neurological data must be
within ±7 days of the time-point response date, otherwise the
data is considered Bnot available^.
Steroid Use and Dose
Steroid use should be derived from the concomitant medications
on the case report forms and recorded as BYes^, BNo^, or Bnot
available^. A value of BNo^ should be assigned if, at the time-
point, the subject is not on steroids or on physiologic replacement
doses only (<1.5 mg dexamethasone or equivalent per day).
Steroid dose should be derived from the concomitant med-
ications on the case report forms. Average steroid dose no
greater than 2 mg change from baseline should be abstracted
to Bstable^. If outside this range the steroid dose should be
abstracted to Bincreased^ or Bdecreased^ accordingly. Steroid
data should be within ±5 days of the time-point response date,
otherwise the data is considered Bnot available^.
Overall Objective Status
The overall objective status for an evaluation should be deter-
mined by combining the patient’s radiographic response on tar-
get lesions, new disease, neurological status, and steroid dose/
usage as defined in Table 3 for patients with measurable
(>10mm x 10mm) disease. Note that patients with possible
PsP or pseudoresponse should be given the Objective Status of
BPreliminary Progression^ or BPreliminary Response^, respec-
tively. Once PsP, pseudoresponse, or true progression/response
are confirmed, the Objective Status can be changed accordingly.
Detailed Modified Radiographic Response
Assessment Rubric
In order to provide both clinical guidelines for continuing
therapy beyond suspected radiographic progression if the
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treating physician believes there may be a therapeutic
benefit and to provide criteria for defining progression
and early drug failure while also allowing for the possi-
bility of PsP and PsR, a modified response rubric similar
to those described recently [97] should be employed. Two
different rubrics should be used depending on whether the
patient is newly diagnosed or enrolled in a trial for recur-
rent disease.
It is important to note that the primary differences
between conventional RANO and the proposed modified
criteria are: (1) use of the post-radiation time point as the
baseline for response evaluation in newly diagnosed GBM
and (2) considering only objectively defined, measurable
enhancing disease in the definition of response and pro-
gression (i.e. exclusion of qualitatively assessed T2/FLAIR
changes).
Newly Diagnosed GBM (Fig. 3)
Newly diagnosed GBM patients will initially undergo a pre-
entry MRI scan for initial diagnosis prior to entry in the study
and prior to therapy. The post-operative scan [MRI(0)] is
Table 3 Guidelines for determining comprehensive objective status
Target lesions
(current scan)
Target lesions (previous
scan)
New sites of
measurable
diseasea
Neurological
status
Steroid
usage
Steroid dose Overall objective
status
CR Not Evaluated No Stable/Better No N/A Preliminary CR
PR Not Evaluated No Stable/Better Any Stable/Decreasing Preliminary PR
PD Not Evaluated Yes or No Stable/Better Any Stable/Increasing Preliminary PD
PD Preliminary or Confirmed PR/CR No Stable/Better Any Stable/Increasing Preliminary PD
SD Preliminary or Confirmed
CR/PR or SD/NE
No Stable/Better Any N/A SD
PR Preliminary PR Yes or No Stable/Better Any Stable/Decreasing Confirmed PR
SD Preliminary PR Yes or No Stable/Better Any Stable/Decreasing SD (Preliminary PR
→Confirmed PR)
SD Preliminary CR Yes or No Stable/Better Any Stable/Decreasing SD (Preliminary CR
→Confirmed CR)
CR Preliminary CR No Stable/Better No N/A Confirmed CR
SD Preliminary PD No Stable/Better Any Stable/Decreasing SD
(Confirmed PsP)
CR/PR/SD
PD/NE
CR/PR/SD/PD/NE Yes or No Worse Any Stable/Increasing Confirmed PD
PD Preliminary PD Yes or No Any Yes Stable/Increasing Confirmed PD
aNote that new sites of measurable disease are added to the sum of bidimensional products or total lesion volume, or constitutes preliminary PD in the
case of no measurable disease at baseline or best response
Fig. 3 Modified radiographic response assessment rubric for management of both pseudoprogression and pseudoresponse in newly diagnosed
glioblastoma
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desired in order to assess residual enhancing disease volume
for use as a covariate in survival analyses, as described previ-
ously. Patients will then start on standard or experimental
therapy with concurrent radiation therapy (RT). The Post-RT
scan [MRI(1)] will be required and used as the baseline scan
for which response will be determined.1 Following the first
cycles of adjuvant therapy, patients will receive additional
requiredMRI scans [MRI(N)].
Recurrent GBM (Fig. 4)
Recurrent GBM patients will undergo a pre-entry MRI
scan [MRI(0)] at the time of recurrence. At the time of
study entry, two scans to confirm progression should be
submitted consisting of at least one scan at the time of
progression and one scan at Nadir or baseline. If the pa-
tient undergoes surgery (optional), then the post-surgical,
pre-treatment MRI can be used as the baseline [MRI(1)],
assuming it is obtained < 72 hours from surgery to reduce
post-operative reactive enhancement [91, 98]. (Note: If
the post-operative MRI scan is used as the baseline refer-
ence, the standardized MRI protocols must be used.) If the
patient does not go to surgery or if the start of treatment
is > 21 days from the start of therapy, the patient will
undergo a pre-treatment MRI [MRI(1)] scan as the base-
line scan for which response will be determined.
Following the first cycles of therapy, patients will receive
additional MRI scans [MRI(N)].
Details Common to Both Newly Diagnosed and Recurrent
GBM
Preliminary Radiographic Progression If the lesion size has
increased ≥25% sum of bidirectional product or ≥40% in vol-
ume between MRI Scan 1 and N, these patients should be
categorized as Bpreliminary radiographic progression^. If the
investigator believes the patient can safely continue on thera-
py, then they should continue to treat and acquire a follow-up
confirmatory scan [MRI(N + 1)] at the next scan interval (8
weeks ± 4 weeks from MRI Scan (N) or no less than 4 weeks
minimum duration between preliminary PD and confirmed
PD scans) to verify tumor growth and progression. For pa-
tients with gross-total resection (GTR) and no measurable
enhancing disease, preliminary radiographic progression is
defined as a transition from no measurable disease to non-
measureable (but present) disease (<10mm x 10mm) or mea-
surable disease (>10mm x 10mm). If the investigator feels it is
safe to keep the patient on, a confirmatory scan at MRI(N + 1)
should be obtained to verify tumor progression.
Confirmed Progression If the patient has an increase ≥25%
sum of bidirectional product or ≥40% in volume betweenMRI
Scan N and N + 1, this is BConfirmed Progression^, the pa-
tient should stop therapy and the date of radiographic progres-
sion is the date of suspected progression, MRI(N). If the pa-
tient has SD/PR/CR on MRI(N + 1) with respect to MRI(N),
PsP is confirmed and the patient should continue on therapy.
Patients will then continue on therapy and receive additional
follow-up MRI scans [MRI(M)]. If the lesion size has in-
creased ≥25% sum of bidirectional product or ≥40% in vol-
ume on MRI(M) relative to the smaller of Nadir or MRI(N +
1), then the patient has BConfirmed Progression^, the patient
should stop therapy and the date of radiographic progression
is the new date, MRI(M). For patients with no measurable
disease at the Post-RT baseline, BConfirmed Progression^will
be defined as a transition from non-measurable (but present)
1 Note the post-surgical, pre-RT scan is often corrupted with post-surgical
blood products and other surgical changes. Further, it is difficult to standardize
in terms of post-surgical timing, where delays in scanning often lead to in-
creased T1 shortening on pre-contrast T1-weighted images due to blood prod-
ucts, etc., and therefore may not be an adequate representation of baseline
tumor burden.
Fig. 4 Modified radiographic response assessment rubric for recurrent glioblastoma
316 Ellingson et al.
disease (<10mm x <10mm) onMRI(N) tomeasurable disease
(>10mm x 10mm) onMRI(N + 1). For patients with confirmed
PsP and no measurable disease at Nadir, BConfirmed
Progression^ should be defined as a transition from no mea-
surable disease to measurable disease (>10mm x 10mm). In
all cases, patients with confirmed progression should stop
therapy.
Preliminary & Confirmed Radiographic Response If a
measurable lesion has decreased ≥50% sum of bidirectional
product or ≥65% in volume between MRI(1) and MRI(N),
these patients should be categorized as Bpreliminary radio-
graphic responders^ and will be monitored for an additional
time point and/or treatment cycle. After an additional cycle of
therapy (8 weeks ± 4 weeks from MRI(N)), patients will re-
ceive a confirmatory MRI(N + 1). If the lesion(s) have in-
creased ≥25% sum of bidirectional product or ≥40% in vol-
ume from MRI(N) (indicating radiographic progression from
MRI(N)), this is considered an Bunsustained radiographic
response^ or Bpseudoresponse^. The date of radiographic pro-
gression for these patients will be MRI(N + 1) and the patient
should stop therapy. Alternatively, if the lesion has not in-
creased from MRI(N), this is considered a Bdurable radio-
graphic response,^ the patient will continue on therapy, and
the date of preliminary radiographic progression is the time
point of an increase ≥25% sum of bidirectional product or
≥40% in volume (from Nadir) during the remainder of the
study. The investigator can then decide whether to continue
safely on therapy until progression has been confirmed and at
the subsequent time point stop therapy if they feel the patient
cannot safely continue therapy.
Stable Disease If the lesion size has not increased or de-
creased beyond the set thresholds between Scan 1 and N,
the patient is considered Bstable.^ Such patients will con-
tinue on therapy, and the date of preliminary progression
is the time point of an increase ≥25% sum of bidirectional
product or ≥40% in volume (from Nadir) during the re-
mainder of the study. Upon preliminary progression the
investigator can choose to either continue therapy and
confirm progression or discontinue therapy. For cases
with significant neurologic decline at the time of imaging
progression as determined from MRI(N), a confirmatory
scan at time point MRI(N + 1) may not be possible or neces-
sary. For these cases, it is appropriate to define MRI(N) as the
progression time point.
Conclusions
Although radiographic response assessment is imperfect and
many nuances exist, changes in contrast enhancing tumor are
both clinically meaningful and appropriate for evaluating
efficacy of new treatments in GBM. The outlined modifica-
tions in this report are meant to both build on the strengths of
the current RANO criteria while providing potential solutions
for many of the common challenges.
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